A prospective, multicentre, randomized, open-label, parallel group study compared the efficacy, safety and tolerability of cefuroxime 750 mg iv administered either twice daily (bd) or three times daily (tds) for 48-72 h, followed by oral cefuroxime axetil 500 mg bd for 5-7 days in a sequential therapy regimen for the treatment of acute exacerbations of chronic bronchitis. A total of 628 adult patients entered the study; 323 in the cefuroxime tds group and 305 in the cefuroxime bd group. For clinically evaluable patients, the post-treatment clinical response rate was 86% and 88% in the cefuroxime tds and bd groups, respectively. Cure was maintained at follow-up (14-28 days after treatment completion) in 85% of the cefuroxime tds group and 84% of patients in the cefuroxime bd group. A total of 189 pathogens was isolated, the most common being Haemophilus influenzae (17%), other Haemophilus spp. (15%), Streptococcus pneumoniae (15%) and Enterobacteriaceae (23%). At the post-treatment assessment, 66% and 70% of pathogens were cleared in the cefuroxime tds and bd groups, respectively. Both treatment regimens were well tolerated. The incidence of drug-related adverse events was 7% in the cefuroxime tds group and 6% in the cefuroxime bd group; the most common side-effects were gastrointestinal. Qualitative and quantitative markers were used to determine the optimal time to switch from iv to oral therapy and, of these, peak expiratory flow rate was shown to be the most useful in the present study. In conclusion, the findings of this study support the use of a bd dosing schedule of cefuroxime in a sequential therapy regimen with oral cefuroxime axetil, demonstrating it to be clinically equivalent to the standard tds dosage currently used, as well as being simpler and more convenient to administer at a lower cost.
Introduction
Patients with chronic bronchitis suffer frequent acute bacterial exacerbations of their illness, especially during the winter months. Those with a severe acute exacerbation of chronic bronchitis (AECB) may require hospitalization and, as the cause of infection is usually unknown, initially receive empirical treatment with broad-spectrum parenteral antibiotics. 1 The symptoms of infection often resolve within 48-72 h 2,3 but approved therapy regimens are usually continued for about 7-10 days to ensure complete eradication of pathogens from the site of infection and to prevent recurrent infection.
Increasing demands on limited healthcare resources have led to the development of a sequential therapy approach, where an initial short course of parenteral therapy is followed by a change to oral treatment usually after 2-3 days. 4 This not only reduces drug costs but also decreases the risk of adverse effects associated with iv therapy such as phlebitis and nosocomial infections, reduces clinical workload, improves patient comfort and mobility, and may allow earlier discharge from hospital. 3, 4 In sequential therapy the same antibiotic is used for the iv and oral phases. 5 Cefuroxime is currently the onlylactamase-stable cephalosporin antibiotic that is available in both oral and parenteral preparations. Cefuroxime axetil is an orally administered prodrug which is de-esterified in the intestinal mucosa to cefuroxime and absorbed into the 863 Sequential therapy with cefuroxime followed by cefuroxime axetil in acute exacerbations of chronic bronchitis circulation. 6 Cefuroxime has broad-spectrum bactericidal activity and has good in-vitro activity against the most common bacterial pathogens responsible for communityacquired respiratory tract infections such as Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. 7 In clinical studies, cefuroxime and cefuroxime axetil were well-tolerated and effective in the treatment of a variety of infections including lower respiratory tract infection (LRTI). 2, 8 A previous comparative clinical trial of two different modalities of switch therapy, i.e. cefuroxime iv/cefuroxime axetil oral compared with co-amoxiclav iv/oral, demonstrated the clinical and bacteriological efficacy and safety of sequential therapy with iv cefuroxime followed by oral treatment with cefuroxime axetil for the treatment of LRTIs using the current regimen of cefuroxime 750 mg iv administered three times daily (tds) followed by oral cefuroxime axetil 500 mg twice daily (bd). 9 Pharmacokinetic studies in healthy volunteers and in patients with LRTI have shown that the levels of cefuroxime attained in both serum and sputum exceed the MICs for the most common respiratory pathogens (MIC 90 2 mg/L) for up to 8 h after dosing with either iv cefuroxime or oral cefuroxime axetil. [10] [11] [12] This suggests that a simplified sequential therapy regimen of bd iv cefuroxime followed by the standard oral cefuroxime axetil 500 mg bd may be as effective as the tds dosing regimen.
The aims of the present study were to compare the clinical and bacteriological efficacy, safety and tolerance of cefuroxime 750 mg iv administered either bd or tds for 48-72 h followed by oral cefuroxime axetil 500 mg bd for 5-7 days in the treatment of AECB.
Subjects and methods
A prospective, randomized, open-label, parallel-group study was conducted at 50 centres in nine countries (the Czech Republic, Germany, Hungary, Israel, Poland, Portugal, Republic of Ireland, Switzerland and the UK). Regulatory approval was obtained where required and all patients gave their written informed consent to participate in the study which was approved by local Ethics Committees in each country.
Patients
Male or female patients aged 18 years or older, who had been diagnosed by the attending physician to have moderate or severe AECB which warranted hospitalization and iv antibiotic treatment, were recruited. Chronic bronchitis is defined as a condition characterized by cough and excessive secretion of mucous in patients who have coughed up sputum on most days during three consecutive months for more than two successive years. The severity of infection was judged subjectively by each investigator by assessing the patient's signs and symptoms of bronchitis such as volume and purulence of sputum, frequency and severity of cough, dyspnoea, smoking history and comorbid risk factors. Patients were judged to have moderate dyspnoea, if for example, they had a mean peak expiratory flow rate (PEFR) of about 300 L/min, and severe dyspnoea if they had a mean PEFR of <250 L/min.
To be eligible to enter the study, patients had to have at least two of the following symptoms: increased frequency and severity of cough, an increase in the volume and/or purulence of sputum, increased dyspnoea, and auscultatory findings consistent with bronchitis. Patients were excluded if they had community-or hospital-acquired pneumonia, radiographic evidence of pneumonia, known hypersensitivity to cephalosporins or penicillins, had received systemic antibiotic therapy during the previous 48 h unless there had been no clinical response, had pathogens known to be resistant to cefuroxime, had bronchial carcinoma, pulmonary tuberculosis or pneumonia caused by atypical pathogens, were immunocompromised, had marked renal impairment, were terminally ill or required assisted ventilation, or were pregnant or breast-feeding.
Treatment and assessments
Patients underwent a pre-study clinical assessment within the 24 h before commencing study treatment, including measurements of PEFR and a chest X-ray. A sample of sputum was obtained for bacteriological culture and susceptibility testing to cefuroxime and ampicillin. Gram's stain was used to test the validity of sputum samples, where a valid sample was defined as containing fewer than ten epithelial cells and 25 leukocytes per low power field. Pathogens were also tested to identify -lactamaseproducing organisms.
Patients were randomly assigned to treatment with either cefuroxime sodium 750 mg iv tds for 48-72 h (six to nine doses) followed by oral cefuroxime axetil 500 mg bd for 5-7 days (the cefuroxime tds group), or cefuroxime sodium 750 mg iv bd for 48-72 h (four to six doses) followed by oral cefuroxime axetil 500 mg bd for 5-7 days (the cefuroxime bd group). Cefuroxime was administered by slow iv injection or infusion. Cefuroxime axetil, two 250 mg tablets, was taken bd after meals. Concurrent administration of other antibiotics was not permitted. Details of all concurrent medications including bronchiodilators, oral steroids and diuretics were recorded. The present study was conducted on an open-label basis and could not be 'blinded' because of the timing of the iv treatment, which was given twice or three times daily.
An interim assessment of the patient's clinical response and signs and symptoms of infection and PEFR measurement was performed at 48-72 h, at the time when treatment was changed from iv to oral therapy. The total number of iv doses administered was recorded. A post-treatment assessment was performed 12-48 h after stopping oral treatment and included a clinical assessment and PEFR measurement; where appropriate, sputum samples were obtained. A further follow-up clinical assessment was made 14-28 days after stopping treatment.
Clinical response was evaluated post-treatment and at follow-up, and was classified as cure, improvement, failure, relapse or unevaluable. 'Cure' was defined as the resolution of clinical signs and symptoms of infection present on entry to the study, 'improvement' was defined as incomplete resolution of clinical signs and symptoms, 'failure' was defined as an inadequate response to therapy requiring additional or alternative antibiotics, and 'relapse' was defined as the recurrence of clinical signs and symptoms of the initial infection during the follow-up period after initial cure or improvement at the post-treatment assessment. No formal analysis of the use of concurrent medications was carried out. Bronchodilators and oral steroids were allowed in all patients as considered necessary by the investigators.
Bacteriological response was evaluated after treatment and was classified as clearance, partial clearance, failure, colonization, superinfection or unevaluable. 'Clearance' was defined as absence of the original pathogen(s) in the post-treatment specimen, 'partial clearance' was the elimination of at least one of multiple pathogens, and 'failure' was defined as the persistence of the original pathogen(s) in the post-treatment sample. 'Colonization' was defined as isolation of a new organism during or up to 2 days after treatment which required no further therapy, whereas 'superinfection' was defined as isolation of a new organism during or up to 2 days after treatment which required further therapy.
Safety and tolerability were assessed by monitoring all adverse events reported during the study. For each adverse event, the date of onset, frequency, severity, outcome, action taken and the possible relationship with the study drug were recorded. A blood sample was taken for routine haematology evaluation on entry to the study and repeated at the end of treatment for patients with abnormal pretreatment values.
Analysis
Using the assumption that a clinical cure/improvement rate of 80% would be achieved by both treatment regimens, it was estimated that a sample size of 251 evaluable patients in each treatment group would be required to demonstrate a 10% difference in clinical cure/improvement rate, with 80% power and a 5% level of significance. To allow for 15% unevaluability, a total of 592 patients was required to enter the study (296 in each treatment group).
All patients randomized to treatment who received at least one dose of study medication were included in the safety analysis (intent-to-treat population). Patients were clinically evaluable if they met the entry criteria and did not have a major protocol violation, and were bacteriologically evaluable if they were clinically evaluable and had a pathogen isolated from a pre-treatment sputum. In this paper, the clinical response and resolution of signs and symptoms of infection are presented for the clinically evaluable population of patients, but were also analysed on an intent-to-treat basis.
The treatment regimens were considered to be clinically equivalent if the 90% confidence limits for the difference in the proportion cured/improved at the post-treatment assessment of clinical response were within the range 10%. The confidence interval was calculated using the normal approximation to the binomial distribution. 13 Similarly, bacteriological equivalence was demonstrated with respect to the post-treatment bacteriological response if the 90% confidence interval for the difference in the proportion cleared was within 10% for the bacteriologically evaluable population.
The proportion of patients who withdrew from the study was compared using the Mantel-Haenszel chi-square test without continuity correction and stratified by country 14 to ensure that withdrawal from the study was independent of treatment. All statistical tests were carried out at the two-sided 5% level of significance.
Results

Patient demographic and baseline characteristics
A total of 628 patients entered this study; 323 received cefuroxime tds and 305 cefuroxime bd. All patients were admitted to hospital with a clinical diagnosis of AECB. Patient demography and characteristics were similar in the two treatment groups (Tables I and II) . The pre-treatment signs and symptoms of infection were similar in the two groups: 98% of patients presented with cough, 92% with dyspnoea, and 93% with wheeze and/or crepitations. In addition, 95% of the patients produced sputum, which was purulent in 26%, mucopurulent in 54%, and mucoid in 15% of patients. The majority of patients, 94% in the cefuroxime tds group and 93% in the cefuroxime bd group, received concurrent medications, most commonly for cardiovascular and respiratory conditions, e.g. ischaemic heart disease, heart failure, obstructive bronchitis or bronchial asthma. The distribution of co-morbid risk factors was generally similar in both groups.
All 628 patients were included in the intent-to-treat population and in analysis of safety data. Of these 628 patients, 522 were clinically evaluable; 267 patients in the cefuroxime tds group and 255 patients in the cefuroxime bd group. The bacteriologically evaluable population comprised 159 patients; 77 in the cefuroxime tds group and 82 in the cefuroxime bd group. The number of patients who withdrew from the study and the timing of withdrawal were similar for each treatment group. There was no significant difference between treatment groups with respect to reasons for withdrawal from the study (P 0.169).
In the clinically evaluable population, 72/267 (27%) patients in the cefuroxime tds group received iv therapy for 48 h (six doses) and 192/267 (71%) for 56-72 h (seven to nine doses). In the cefuroxime bd group, 68/255 (27%) patients received iv therapy for 48 h (four doses) and 183/255 (82%) for 60-72 h (five or six doses). In addition, 48/267 (18%) patients in the cefuroxime tds group and 44/255 (17%) patients in the cefuroxime bd group were discharged from hospital once they had started oral therapy to complete their oral treatment at home. The others were considered by the investigators as not ready for early discharge: they were observed in hospital until the post-treatment assessments had taken place. 
Clinical response
The clinical response at the post-treatment and follow-up assessments for the clinically evaluable patients in both treatment groups are presented in Figure 1 . The number of patients judged to be cured or improved following treatment was 230/267 (86%) in the cefuroxime tds group and 225/255 (88%) in the cefuroxime bd group. The 90% confidence interval for the difference in clinical response ( 7%, 3%) was contained within the equivalence interval ( 10%), therefore, the treatment groups were considered clinically equivalent. Cure was maintained in the majority of patients in both the cefuroxime tds (85%) and cefuroxime bd (84%) groups when assessed at follow-up 14-28 days after completion of oral therapy. The intent-to-treat analysis also demonstrated that the cefuroxime bd dosing regimen was equivalent to the cefuroxime tds dosing regimen over the course of the study.
Effect of severity of infection
The severity of infection was classified by each investigator's subjective rating of patient's signs and symptoms of bronchitis such as PEFR, sputum volume and purulence, frequency and severity of cough, and co-morbid risk factors. The mean age of the patients was 63 years, the mean PEFR was 204 L/min, 98% of the patients had cough, 92% had dyspnoea and auscultatory findings and 81% produced purulent or mucopurulent sputum. These were comparable in the two treatment groups. All patients classified by the investigators to have a mild infection (7/7; 100%) were cured/improved at the post-treatment assessment. However, the majority of patients recruited to the study were classified by the investigators to have had moderate to severe disease requiring hospitalization and thus the emphasis was placed on the success rate of treatment in patients at this end of the spectrum. In patients with moderate infection 164/183 (90%) patients in the cefuroxime tds group and 164/186 (88%) patients in the cefuroxime bd group were cured/improved at the posttreatment assessment. Similarly in patients with severe infection, 63/81 (78%) patients in the cefuroxime tds group and 57/65 (88%) patients in the cefuroxime bd group were cured/improved at this point.
Signs and symptoms of infection
The resolution of the signs and symptoms of AECB for the clinically evaluable population are shown in Figure 2 . Compared with pre-treatment values, the proportions of patients with cough, dyspnoea, abnormal auscultatory findings and sputum production were decreased at the interim assessment after 48-72 h iv therapy and decreased even further at the end of oral treatment. The degree of purulence of the sputum decreased during the study is shown in Figure 3 . In both treatment groups the percentage of patients with purulent sputum decreased from a pretreatment value of 27%, to 3% and 1% at the interim and post-treatment assessments, respectively. For the clinically evaluable population, most patients demonstrated an improvement in PEFR within the first 48 h, and patients with a low baseline PEFR (<250 L/min) tended to show the most marked improvement; 45% of those with low baseline PEFR showed 20% improvement with iv therapy. Mean PEFR increased from a pre-treatment value of 206 to 255 L/min at the interim analysis and then to 289 L/min post-treatment in the tds group, similarly from 202 to 246 L/min and then to 287 L/min in the bd group. The resolution of the signs and symptoms of infection for the intention-to-treat population was similar to that in the clinically evaluable population.
Bacteriological response
In both treatment groups, positive pre-treatment sputum samples were obtained from around 38% of patients, 4% of patients were excluded from the bacteriologically evaluable population due to the presence of a resistant pathogen and a further 4% of patients were excluded because the susceptibility of all pre-treatment pathogens to cefuroxime was unknown. A total of 189 pathogens was isolated from 159 patients as some patients had more than one pathogen, 95 pathogens from 77 patients in the tds group and 94 pathogens from 82 patients in the bd group. The distribution of the pre-treatment pathogens is shown in Figure 4 , and the bacteriological response in Table III . The percentage of patients who were bacteriologically cleared post-treatment was 73% and 87% in the cefuroxime tds and cefuroxime bd groups, respectively. The difference in the proportion cleared post-treatment between the two treatment groups was 14%, with a 90% confidence interval of -24%, -3%, but the comparison lacked sufficient power to demonstrate bacteriological equivalence because of the relatively low number of patients with positive pre-treatment bacteriology. 
Adverse events
Of the 628 patients who entered the study, 79/323 (24%) patients in the cefuroxime tds group and 65/305 (21%) in the cefuroxime bd group reported an adverse event.
Adverse events were considered to be drug-related in 7% of patients in the cefuroxime tds group and 6% of patients in the cefuroxime bd group. The most commonly reported adverse events during treatment were gastrointestinal (abdominal discomfort and pain, dyspepsia, and nausea and vomiting) in 6% and 4% of patients in the cefuroxime tds and bd groups, respectively and cardiovascular (tachyarrhythmias, hypertension and cardiac failure) in 4% of patients in both groups: mostly they occurred during the oral treatment phase. The serious adverse events reported and the number of deaths were similar in each treatment group, 14 (4%) and 10 (3%) in the tds and bd group, respectively. Two patients died and four adverse events were considered by the investigators to be probably drug-related. The two patients who died were elderly patients. One death was due to chronic obstructive airways disease; the patient was 73 years old and had 15 years' history of chronic obstructive airways disease. The other death was due to renal failure; the patient was 79 years old and had a history of heart failure, atrial fibrillation, hypertension and diabetes mellitus. The other four serious adverse events were bullae, erythema and pruritis, allergic reactions, bacterial superinfection, and acute gastritis. Overall, there were no clinically relevant differences between the two treatment groups with regards to safety and tolerability.
Discussion
Antibiotics are widely used in the treatment of LRTIs such as AECB and pneumonia, both in hospitals and in the community. However, the routes of administration vary between different European countries. 15 Parenteral therapy is expensive in terms of drug costs, medical personnel time, and days spent in hospital, but has the advantage of rapidly achieving effective antibiotic concentrations in the early stages of infection when patients, particularly the elderly, may be nauseous or confused and unable to take oral treatment. Nevertheless, efforts to shorten or modify treatment regimens without loss of efficacy may result in improved compliance and substantial costsavings. 5 Such economic considerations have contributed to the increasing use of sequential therapy over the last few years, and a wide range of antibiotics in various iv and oral combinations have been used. 4, 5 Intravenous cephalosporins such as cefotaxime, ceftazidime or ceftriaxone have been followed by treatment with oral cephalosporins such as cefuroxime and cefixime or quinolone. 3 Cefuroxime is available in both parenteral and oral forms to enable the same antibiotic to be used in sequential therapy.
Cefuroxime has a broad spectrum of antibacterial activity and is -lactamase-stable, making it particularly suitable for the treatment of LRTIs, where the causative pathogen is usually unknown. The clinical efficacy of parenteral cefuroxime and oral cefuroxime axetil in treating LRTIs has been well established in more than ten large well-controlled clinical studies. Moreover, a sequential therapy regimen of iv cefuroxime followed by oral cefuroxime axetil has been shown to be as effective as amoxycillin plus clavulanic acid in the treatment of LRTI. 9 The present study examined whether the current tds cefuroxime regimen for bronchitis can be simplified without loss of efficacy. The results showed that, in patients hospitalized with acute exacerbation of chronic bronchitis, cefuroxime 750 mg iv bd followed by oral cefuroxime axetil 500 mg bd was as well-tolerated and effective as the standard dosing regimen of cefuroxime 750 mg iv tds followed by oral cefuroxime axetil 500 mg bd. There was a high clinical response rate and a low relapse rate in both treatment groups, indicating the sustained eradication of pathogens and supporting previous findings. 9 The rationale for bd and tds iv cefuroxime being equivalent in terms of efficacy was based on a clear understanding of the integration of the pharmacokinetics and pharmacodynamics of cefuroxime. All -lactam antibiotics, including cefuroxime, show time-dependent rather than concentration-dependent killing. 16 The length of time that antibiotic plasma levels are above the MIC is the most important factor for bactericidal activity, and the minimum period necessary to produce a bacteriostatic effect in neutropenic animals is 35-40% of the dosing interval. 16 Using the pharmacokinetic profiles of cefuroxime 750 mg iv bd and tds, and cefuroxime axetil 500 mg bd obtained from previous studies in healthy volunteers, 11, 17 the time period during which serum levels of cefuroxime are maintained above an MIC of 2 mg/L were calculated as 46%, 69% and 38% of the dosing interval, respectively. This suggests that all the dosing regimens used in the present study are sufficient to have activity against the most common pathogens in LRTI. The results of the present study support this.
The most common pathogens in LRTIs are H. influenzae, S. pneumoniae and M. catarrhalis, 1, 18 and these pathogens were isolated in the current study. Since increasing numbers of strains of H. influenzae and M. catarrhalis produce -lactamases, there is a clear need for antibiotics, such as cefuroxime, which are -lactamasestable. 7 Moreover, the incidence of S. pneumoniae strains with intermediate and high resistance to penicillin has been increasing worldwide. Although all currently availablelactam antibiotics are ineffective against highly resistant strains of S. pneumoniae, cefuroxime is one of the more active cephalosporins against strains with intermediate resistance. 7 In sequential therapy regimens, the decision of when to switch from iv to oral therapy is not rigid. In this study, an interim analysis demonstrated the usefulness of markers such as PEFR in determining the optimal time to switch to oral therapy. Mean PEFR had improved in both treatment groups at the time of switching to oral therapy and this improvement was maintained during oral treatment and at follow-up. Thus, PEFR might be a useful indicator of the efficacy of treatment in bacterial exacerbations of bronchitis and a marker for optimal time to change to oral therapy. 19 There are several advantages to an early switch from iv to oral therapy, and this change in treatment is determined primarily by the severity of the infection and the clinical status of the patient. In the present study, about 90% of patients were able to switch to oral therapy, and only 10% of patients withdrew from the study due to lack of efficacy. Moreover, the majority of patients in both treatment groups switched to oral therapy within 48-72 h.
During oral therapy about 18% of patients were discharged from hospital and were able to complete their treatment at home. The others were considered by the investigators as not ready for early discharge due to concurrent medical conditions. This highlights the advantage of sequential therapy in shortening hospital stay. A previous study showed that sequential therapy with cefuroxime in patients with respiratory tract infections could shorten hospital stay by more than 3 days. 20 An early discharge from hospital has also been suggested to improve patient compliance, improve recovery and reduce the risk of acquiring a hospital infection. 4 Sequential therapy has been shown to be more cost-effective than a full course of iv therapy, 3, 21, 22 mainly due to the shortened duration of hospitalization. 23 Costs were not analysed in the present study, although it is anticipated that a reduction in the dosing interval of iv cefuroxime from tds to bd will lead to additional cost savings in terms of drug costs and resource utilization associated with the preparation, dispensing and administration of iv therapy.
It is possible that at least some of the patients recruited to the study could have received only oral therapy and might possibly have been managed in the community. Oral therapy may be as good as iv and this trend is likely to increase. 24, 25 However, about 10% of our patients were unable to change to oral therapy for whatever reason and required a longer (>72 h) course of iv therapy. Therefore, careful classification of patients would be required to identify which route of administration was necessary. Additionally only patients deemed to need iv therapy and hospitalization were included in this study.
The safety and tolerability of cefuroxime have already been well established and the findings of the present study confirm this, with a low overall incidence of adverse events, which was comparable for the two treatment groups, and no unexpected adverse events. In conclusion, this study has clearly shown that bd and tds iv cefuroxime are clinically equivalent in terms of efficacy and tolerability when used in a sequential therapy regimen with oral cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis. A twice-daily dosing schedule of cefuroxime is simpler and more convenient to administer and should provide further cost-savings without loss of effectiveness.
